1
|
Guo DG, Wang HJ, Zhou Y, Liu XL. Advances in chromone-based reactants in the ring opening and skeletal reconstruction reaction: access to skeletally diverse salicyloylbenzene/heterocycle derivatives. Org Biomol Chem 2022; 20:4681-4698. [PMID: 35617020 DOI: 10.1039/d2ob00478j] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Salicyloylbenzene/heterocycles are privileged scaffolds found in many natural products and bioactive molecules. Numerous useful approaches for the preparation of these privileged scaffolds have been developed in recent years. Among these approaches, chromone-based reactants have demonstrated their importance in the synthesis of these salicyloylbenzene/heterocycle scaffolds with structural complexity and potential biological appeal. In this review, the recent advances in the synthesis of salicyloylbenzene/heterocycles are summarized and discussed according to the chromone-based reactants which could be achieved in one step via ring-opening and skeletal reconstruction reactions. Both the mechanisms and the applications of the corresponding products in organic and medicinal chemistry are also described.
Collapse
Affiliation(s)
- Dong-Gui Guo
- National & Local Joint Engineering Research Center for the Exploitation of Homology Resources of Southwest Medicine and Food, Guizhou University, Guiyang, Guizhou 550025, P. R. China. .,College of Food and Pharmaceutical Engineering, Guizhou Institute of Technology, Guiyang 550003, China
| | - Hui-Juan Wang
- National & Local Joint Engineering Research Center for the Exploitation of Homology Resources of Southwest Medicine and Food, Guizhou University, Guiyang, Guizhou 550025, P. R. China.
| | - Ying Zhou
- College of Pharmaceutical Sciences, Guizhou University of Chinese Medicine, Guiyang, Guizhou 550025, P. R. China
| | - Xiong-Li Liu
- National & Local Joint Engineering Research Center for the Exploitation of Homology Resources of Southwest Medicine and Food, Guizhou University, Guiyang, Guizhou 550025, P. R. China.
| |
Collapse
|
2
|
Wang WN, Liu RM, Zhang L, Liu XL, Dai YF, Yu ZB, Peng LJ. Ring opening and skeletal reconstruction of 3-vinyl benzofuranone-chromone synthons: catalyst-free access to skeletally-diverse 2-pyridone and optically active imidazoline derivatives. Org Biomol Chem 2022; 20:2227-2232. [PMID: 35237774 DOI: 10.1039/d1ob02432a] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Herein is reported the first example of ring opening and skeletal reconstruction of 3-vinyl benzofuranone-chromones 1 as versatile synthons, which can react with ammonia or primary aliphatic amines as binucleophiles, for the eco-friendly and atom-economical synthesis of diverse and functionalized 2-pyridones 3 with potential biological activity in good to excellent yields (77-93%). When using optically active 1,2-diphenylethylenediamine 2 as the binucleophile, the in situ generated 2-pyridone intermediates are successfully transformed to novel optically active functionalized imidazoline derivatives 4 with high efficiency (up to 87% yield). In particular, this is the first report on the catalyst-free intramolecular cyclization occurring between an amide and a primary aliphatic amine for the construction of imidazoline molecules.
Collapse
Affiliation(s)
- Wei-Na Wang
- National & Local Joint Engineering Research Center for the Exploitation of Homology Resources of Southwest Medicine and Food, Guizhou University, Guiyang, 550025, China.
| | - Ren-Ming Liu
- National & Local Joint Engineering Research Center for the Exploitation of Homology Resources of Southwest Medicine and Food, Guizhou University, Guiyang, 550025, China.
| | - Lei Zhang
- National & Local Joint Engineering Research Center for the Exploitation of Homology Resources of Southwest Medicine and Food, Guizhou University, Guiyang, 550025, China.
| | - Xiong-Li Liu
- National & Local Joint Engineering Research Center for the Exploitation of Homology Resources of Southwest Medicine and Food, Guizhou University, Guiyang, 550025, China.
| | - Yi-Feng Dai
- National & Local Joint Engineering Research Center for the Exploitation of Homology Resources of Southwest Medicine and Food, Guizhou University, Guiyang, 550025, China.
| | - Zhang-Biao Yu
- National & Local Joint Engineering Research Center for the Exploitation of Homology Resources of Southwest Medicine and Food, Guizhou University, Guiyang, 550025, China.
| | - Li-Jun Peng
- National & Local Joint Engineering Research Center for the Exploitation of Homology Resources of Southwest Medicine and Food, Guizhou University, Guiyang, 550025, China.
| |
Collapse
|
3
|
Zhang L, Liu RM, Wang WN, Liu XL, Dai YF, Yu ZB, Peng LJ. 3-Vinyl oxindole-chromone synthon as a skeletal reconstruction reactant for the synthesis of 2-hydroxy benzoyl pyridones. NEW J CHEM 2022. [DOI: 10.1039/d1nj06112g] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The first example of 3-vinyl oxindole-chromones in the ring opening and recyclization reaction.
Collapse
Affiliation(s)
- Lei Zhang
- National & Local Joint Engineering Research Center for the Exploition of Homology Resources of Southwest Medicine and Food, Guizhou University, Guiyang, 550025, China
| | - Ren-Ming Liu
- National & Local Joint Engineering Research Center for the Exploition of Homology Resources of Southwest Medicine and Food, Guizhou University, Guiyang, 550025, China
| | - Wei-Na Wang
- National & Local Joint Engineering Research Center for the Exploition of Homology Resources of Southwest Medicine and Food, Guizhou University, Guiyang, 550025, China
| | - Xiong-Li Liu
- National & Local Joint Engineering Research Center for the Exploition of Homology Resources of Southwest Medicine and Food, Guizhou University, Guiyang, 550025, China
| | - Yi-Feng Dai
- National & Local Joint Engineering Research Center for the Exploition of Homology Resources of Southwest Medicine and Food, Guizhou University, Guiyang, 550025, China
| | - Zhang-Biao Yu
- National & Local Joint Engineering Research Center for the Exploition of Homology Resources of Southwest Medicine and Food, Guizhou University, Guiyang, 550025, China
| | - Li-Jun Peng
- National & Local Joint Engineering Research Center for the Exploition of Homology Resources of Southwest Medicine and Food, Guizhou University, Guiyang, 550025, China
| |
Collapse
|
4
|
Wang H, Qin Z, Yan A. Classification models and SAR analysis on CysLT1 receptor antagonists using machine learning algorithms. Mol Divers 2021; 25:1597-1616. [PMID: 33534023 DOI: 10.1007/s11030-020-10165-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2020] [Accepted: 11/27/2020] [Indexed: 12/21/2022]
Abstract
Cysteinyl leukotrienes 1 (CysLT1) receptor is a promising drug target for rhinitis or other allergic diseases. In our study, we built classification models to predict bioactivities of CysLT1 receptor antagonists. We built a dataset with 503 CysLT1 receptor antagonists which were divided into two groups: highly active molecules (IC50 < 1000 nM) and weakly active molecules (IC50 ≥ 1000 nM). The molecules were characterized by several descriptors including CORINA descriptors, MACCS fingerprints, Morgan fingerprint and molecular SMILES. For CORINA descriptors and two types of fingerprints, we used the random forests (RF) and deep neural networks (DNN) to build models. For molecular SMILES, we used recurrent neural networks (RNN) with the self-attention to build models. The accuracies of test sets for all models reached 85%, and the accuracy of the best model (Model 2C) was 93%. In addition, we made structure-activity relationship (SAR) analyses on CysLT1 receptor antagonists, which were based on the output from the random forest models and RNN model. It was found that highly active antagonists usually contained the common substructures such as tetrazoles, indoles and quinolines. These substructures may improve the bioactivity of the CysLT1 receptor antagonists.
Collapse
Affiliation(s)
- Hongzhao Wang
- State Key Laboratory of Chemical Resource Engineering, Department of Pharmaceutical Engineering, University of Chemical Technology, Beijing, People's Republic of China
| | - Zijian Qin
- State Key Laboratory of Chemical Resource Engineering, Department of Pharmaceutical Engineering, University of Chemical Technology, Beijing, People's Republic of China
| | - Aixia Yan
- State Key Laboratory of Chemical Resource Engineering, Department of Pharmaceutical Engineering, University of Chemical Technology, Beijing, People's Republic of China.
| |
Collapse
|
5
|
Santos CMM, Silva VLM, Silva AMS. Synthesis of Chromone-Related Pyrazole Compounds. Molecules 2017; 22:molecules22101665. [PMID: 28981465 PMCID: PMC6151840 DOI: 10.3390/molecules22101665] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2017] [Revised: 09/22/2017] [Accepted: 09/28/2017] [Indexed: 01/06/2023] Open
Abstract
Chromones, six-membered oxygen heterocycles, and pyrazoles, five-membered two-adjacent-nitrogen-containing heterocycles, represent two important classes of biologically active compounds. Certain derivatives of these scaffolds play an important role in medicinal chemistry and have been extensively used as versatile building blocks in organic synthesis. In this context, we will discuss the most relevant advances on the chemistry that involves both chromone and pyrazole rings. The methods reviewed include the synthesis of chromone-pyrazole dyads, synthesis of chromone-pyrazole-fused compounds, and chromones as starting materials in the synthesis of 3(5)-(2-hydroxyaryl)pyrazoles, among others. This review will cover the literature on the chromone and pyrazole dual chemistry and their outcomes in the 21st century.
Collapse
Affiliation(s)
- Clementina M M Santos
- Department of Chemistry & QOPNA, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal.
- School of Agriculture, Polytechnic Institute of Bragança, 5300-253 Bragança, Portugal.
| | - Vera L M Silva
- School of Agriculture, Polytechnic Institute of Bragança, 5300-253 Bragança, Portugal.
| | - Artur M S Silva
- School of Agriculture, Polytechnic Institute of Bragança, 5300-253 Bragança, Portugal.
| |
Collapse
|
6
|
Zhang P, Hong L, Li G, Wang R. Sodium Halides as Halogenating Reagents: Rhodium(III)-Catalyzed Versatile and Practical Halogenation of Aryl Compounds. Adv Synth Catal 2014. [DOI: 10.1002/adsc.201400590] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
7
|
Schmidt JA, Bell FM, Akam E, Marshall C, Dainty IA, Heinemann A, Dougall IG, Bonnert RV, Sargent CA. Biochemical and pharmacological characterization of AZD1981, an orally available selective DP2 antagonist in clinical development for asthma. Br J Pharmacol 2013; 168:1626-38. [PMID: 23146091 DOI: 10.1111/bph.12053] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2012] [Revised: 10/22/2012] [Accepted: 10/25/2012] [Indexed: 01/26/2023] Open
Abstract
BACKGROUND AND PURPOSE The discovery of DP2 as a second receptor for PGD2 has prompted the search for antagonists as potential novel therapies based on the associations between PGD2 and disease. Here we describe the biochemical and pharmacological properties of 4-(acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-1H-indole-1-acetic acid (AZD1981), a novel DP2 receptor antagonist. EXPERIMENTAL APPROACH Binding to DP2 , functional receptor pharmacology and selectivity were studied in both human and animal systems. KEY RESULTS AZD1981 displaced radio-labelled PGD2 from human recombinant DP2 with high potency (pIC50 = 8.4). Binding was reversible, non-competitive and highly selective against a panel of more than 340 other enzymes and receptors, including DP1 (>1000-fold selective). AZD1981 inhibited DP2 -mediated shape change and CD11b up-regulation in human eosinophils, shape change in basophils and chemotaxis of human eosinophils and Th2 cells with similar potency. AZD1981 exhibited good cross-species binding activity against mouse, rat, guinea pig, rabbit and dog DP2 . Evaluation in mouse, rat or rabbit cell systems was not possible as they did not respond to DP2 agonists. Agonist responses were seen in guinea pig and dog, and AZD1981 blocked DP2 -mediated eosinophil shape change. Such responses were more robust in the guinea pig, where AZD1981 also blocked DP2 -dependent eosinophil emigration from bone marrow. CONCLUSIONS AND IMPLICATIONS AZD1981 is a DP2 antagonist that blocks functional responses in eosinophils, Th2 cells and basophils. It exhibited similar potency irrespective of the cell type, DP2 agonist or species used. This selective orally active agent is currently under clinical evaluation as a potential therapeutic agent in respiratory diseases including asthma.
Collapse
Affiliation(s)
- J A Schmidt
- Department of Bioscience, AstraZeneca R&D Charnwood, Loughborough, Leicestershire, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Facile synthesis of novel tetrasubstituted 1-pyrazolines from Baylis–Hillman adducts and acyl diazomethanes. Tetrahedron Lett 2013. [DOI: 10.1016/j.tetlet.2013.05.041] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
9
|
Mauser PJ, House A, Jones H, Correll C, Boyce C, Chapman RW. Pharmacological characterization of the late phase reduction in lung functions and correlations with microvascular leakage and lung edema in allergen-challenged Brown Norway rats. Pulm Pharmacol Ther 2013; 26:677-84. [PMID: 23523662 DOI: 10.1016/j.pupt.2013.03.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/23/2012] [Revised: 03/04/2013] [Accepted: 03/07/2013] [Indexed: 10/27/2022]
Abstract
Late phase airflow obstruction and reduction in forced vital capacity are characteristic features of human asthma. Airway microvascular leakage and lung edema are also present in the inflammatory phase of asthma, but the impact of this vascular response on lung functions has not been precisely defined. This study was designed to evaluate the role of increased lung microvascular leakage and edema on the late phase changes in forced vital capacity (FVC) and peak expiratory flow (PEF) in allergen-challenged Brown Norway rats using pharmacological inhibitors of the allergic inflammatory response. Rats were sensitized and challenged with ovalbumin aerosol and forced expiratory lung functions (FVC, PEF) and wet and dry lung weights were measured 48 h after antigen challenge. Ovalbumin challenge reduced FVC (63% reduction) and PEF (33% reduction) and increased wet (65% increase) and dry (51% increase) lung weights. The antigen-induced reduction in FVC and PEF was completely inhibited by oral treatment with betamethasone and partially attenuated by inhibitors of arachidonic acid metabolism including indomethacin (cyclooxygenase inhibitor), 7-TM and MK-7246 (CRTH2 antagonists) and montelukast (CysLT1 receptor antagonist). Antagonists of histamine H1 receptors (mepyramine) and 5-HT receptors (methysergide) had no significant effects indicating that these pre-formed mast cell mediators were not involved. There was a highly significant (P < 0.005) correlation for the inhibition of FVC reduction and increase in wet and dry lung weights by these pharmacological agents. These results strongly support the hypothesis that lung microvascular leakage and the associated lung edema contribute to the reduction in forced expiratory lung functions in antigen-challenged Brown Norway rats and identify an important role for the cyclooxygenase and lipoxygenase products of arachidonic acid metabolism in these responses.
Collapse
Affiliation(s)
- Peter J Mauser
- Merck Research Laboratories, 2015, Galloping Hill Road, Kenilworth, NJ 07033-0539, USA.
| | | | | | | | | | | |
Collapse
|
10
|
2,4-Dichlorophenoxyacetic Acid Derived Schiff Base and Its Lanthanide(III) Complexes: Synthesis, Characterization, Spectroscopic Studies, and Plant Growth Activity. J CHEM-NY 2013. [DOI: 10.1155/2013/810892] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
2,4-Dichlorophenoxyacetic acid derived Schiff base (HL) and its lanthanide [La(III), Pr(III), Nd(III), Sm(III), Eu(III), Gd(III), Dy(III), Y(III)] complexes were synthesized and characterized by various spectroscopic (1H,13C, DEPT and 2D HMQC NMR, FT-IR, UV-Vis, and mass) techniques and other analytical methods. HL exhibits “E” and “Z” isomerism and was confirmed by variable temperature1H NMR studies. The spectral and analytical data reveals the bidentate coordination of HL to lanthanide(III) ion, through carboxylic acid group via deprotonation. Fluorescence spectrum of europium complex shows bands at 578, 592, and 612 nm assignable toD05→F07,D05→F17, andD05→F27, respectively. Auxin activity of HL and lanthanum(III) complex on wheat seeds (Triticum durum) was measured at different concentrations. The percentage germination, root length, and shoot length were recorded. An enhancement in the plant growth activity of the ligand was observed on complexation and the best activity was observed at 10−6 M concentration.
Collapse
|
11
|
Deppong CM, Green JM. Experimental advances in understanding allergic airway inflammation. Front Biosci (Schol Ed) 2013; 5:167-80. [PMID: 23277043 DOI: 10.2741/s364] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Asthma is largely an inflammatory disease, with the development of T cell mediated inflammation in the lung following exposure to allergen or other precipitating factors. Currently, the major therapies for this disease are directed either at relief of bronchoconstriction (ie beta-agonists) or are non-specific immunomodulators (ie, corticosteroids). While much attention has been paid to factors that regulate the initiation of an inflammatory response, chronic inflammation may also be due to defects in regulatory mechanisms that limit or terminate immune responses. In this review, we explore the elements controlling both the recruitment of T cells to the lung and their function. Possibilities for future therapeutic intervention are highlighted.
Collapse
Affiliation(s)
- Christine M Deppong
- Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
| | | |
Collapse
|
12
|
Abstract
Prostaglandin D2 (PGD2) plays a key role in many of the physiological markings of allergic inflammation including vasodilation, bronchoconstriction, vascular permeability and lymphocyte recruitment. The action of this molecule is elicited through its two primary receptors, DP and CRTH2. Activation of CRTH2 leads to lymphocyte chemotaxis, potentiation of histamine release from basophils, production of inflammatory cytokines (IL-4, IL-5 and IL-13) by Th2 cells, eosinophil degranulation and prevention of Th2 cell apoptosis. As such, antagonism of CRTH2 has been reported to ameliorate the symptoms associated with various allergen challenge animal models including murine antigen induced lung inflammation, murine cigarette smoke induced lung inflammation, murine allergic rhinitis, guinea pig PGD2-induced airflow obstruction, guinea pig airway hyper-responsiveness, sheep airway hyper-responsiveness and murine contact hypersensitivity. CRTH2 antagonists fall into four broad categories: tricyclic ramatroban analogues, indole acetic acids, phenyl/phenoxy acetic acids and non-acid-containing tetrahydroquinolines. Numerous CRTH2 antagonists have been advanced into the clinic and early reports from two Phase II trials suggest promising activity in the alleviation of atopic symptoms.
Collapse
Affiliation(s)
- L. NATHAN TUMEY
- Pfizer Global R&D Worldwide Medicinal Chemistry, MS 8220-3563, 445 Eastern Point Rd Groton, CT 06340 USA
| |
Collapse
|
13
|
Abid Masood M, Gardner M, Dack K, Winpenny D, Lunn G. Use of libraries to access new chemical space: Applications to CRTH2. Bioorg Med Chem Lett 2012; 22:3682-7. [DOI: 10.1016/j.bmcl.2012.04.041] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2011] [Revised: 04/06/2012] [Accepted: 04/07/2012] [Indexed: 11/25/2022]
|
14
|
Plaskon AS, Grygorenko OO, Ryabukhin SV. Recyclizations of 3-formylchromones with binucleophiles. Tetrahedron 2012. [DOI: 10.1016/j.tet.2012.01.077] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
15
|
Pettipher R, Whittaker M. Update on the development of antagonists of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). From lead optimization to clinical proof-of-concept in asthma and allergic rhinitis. J Med Chem 2012; 55:2915-31. [PMID: 22224640 DOI: 10.1021/jm2013997] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Roy Pettipher
- Oxagen Ltd., 91 Milton Park, Abingdon, Oxon OX14 4RY, UK.
| | | |
Collapse
|
16
|
Brunschweiger A, Hall J. A decade of the human genome sequence--how does the medicinal chemist benefit? ChemMedChem 2011; 7:194-203. [PMID: 22170741 DOI: 10.1002/cmdc.201100498] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2011] [Indexed: 12/11/2022]
Abstract
Many have claimed that the sequencing of the human genome has failed to deliver the promised new era of drug discovery and development. Here, we argue that in fact, the availability of the human genome sequence and the genomics technologies that resulted from those research efforts have had a major impact on drug discovery. Medicinal chemists are actively using the data gleaned from structural genomics projects over the past decade to design more selective and more effective drug candidates. For example, large superfamilies of related enzymes, such as the kinome, proteome, proteasome, transportome, identified because of the sequencing of the human genome represent a huge number of potential drug targets. Ten years on, we're able to design multitarget drugs where the selectivity for a certain subgroup of receptors can lead to increased efficacy rather than the side effects traditionally associated with "off-targets". New trends and discoveries in biomedical research are notoriously slow to show their value, and this is also true for genomics technologies. However, the examples we've selected show that these are firmly set in the drug-discovery process, and without the human genome sequence, a number of current clinical candidates and promising drug leads would not have been possible.
Collapse
Affiliation(s)
- Andreas Brunschweiger
- Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Wolfgang-Pauli-Str. 10, 8093 Zurich, Switzerland
| | | |
Collapse
|
17
|
Stebbins KJ, Broadhead AR, Musiyenko A, Barik S, Scott JM, Truong YP, Stearns BA, Hutchinson JH, Prasit P, Evans JF, Lorrain DS. DP2 (CRTh2) antagonism reduces ocular inflammation induced by allergen challenge and respiratory syncytial virus. Int Arch Allergy Immunol 2011; 157:259-68. [PMID: 22042170 DOI: 10.1159/000328769] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2010] [Accepted: 04/20/2011] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND Allergic conjunctivitis is characterized by itchy, watery and swollen eyes which occur in response to exposure to seasonal or environmental allergens. The early phase reaction of allergic conjunctivitis is primarily mediated by mast cell degranulation while the late phase reaction is driven by Th2 cells and eosinophils. Prostaglandin D(2) (PGD(2)), released from mast cells, is present in allergic conjunctival tears and may elicit classical allergic responses via interaction with the high-affinity DP2 receptor (chemoattractant receptor-homologous molecule expressed on Th2 cells, CRTh2). Furthermore, antagonism of this receptor is well known to inhibit eosinophil chemotaxis, basophil activation and Th2 cytokine production. PGD(2), therefore, may be involved in both early and late phase reactions in response to allergen challenge. METHODS Thus, we explored whether our novel and selective DP2 antagonist AM156 would be efficacious in animal models of allergic conjunctivitis. Furthermore, as respiratory syncytial virus (RSV) has been implicated in the pathogenesis of allergic conjunctivitis, we examined the effects of DP2 antagonism in a murine model of RSV ocular infection. RESULTS Utilizing a guinea pig ovalbumin model and a murine ragweed model we demonstrated that AM156 reduces redness, discharge and swelling in response to allergen challenge. These effects were equal to or greater than those of current clinical treatment options for allergic conjunctivitis including topical corticosteroids and a dual-mechanism antihistamine and decongestant. AM156 significantly reduced RSV-induced ocular inflammation and IL-4 production. CONCLUSION These results suggest that a topical DP2 antagonist such as AM156 may represent a novel therapeutic for allergic conjunctivitis.
Collapse
|
18
|
Chen JJ, Budelsky AL. Prostaglandin D₂ receptor CRTH2 antagonists for the treatment of inflammatory diseases. PROGRESS IN MEDICINAL CHEMISTRY 2011; 50:49-107. [PMID: 21315928 DOI: 10.1016/b978-0-12-381290-2.00002-1] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Jian Jeffrey Chen
- Chemistry Research and Discovery, Amgen Inc., One Amgen Center Dr. Thousand Oaks, CA 91320, USA
| | | |
Collapse
|
19
|
Crosignani S, Prêtre A, Jorand-Lebrun C, Fraboulet G, Seenisamy J, Augustine JK, Missotten M, Humbert Y, Cleva C, Abla N, Daff H, Schott O, Schneider M, Burgat-Charvillon F, Rivron D, Hamernig I, Arrighi JF, Gaudet M, Zimmerli SC, Juillard P, Johnson Z. Discovery of Potent, Selective, and Orally Bioavailable Alkynylphenoxyacetic Acid CRTH2 (DP2) Receptor Antagonists for the Treatment of Allergic Inflammatory Diseases. J Med Chem 2011; 54:7299-317. [DOI: 10.1021/jm200866y] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
| | - Adeline Prêtre
- Merck Serono S.A., 9 Chemin des Mines, CH-1202 Geneva, Switzerland
| | | | - Gaële Fraboulet
- Merck Serono S.A., 9 Chemin des Mines, CH-1202 Geneva, Switzerland
| | - Jeyaprakashnarayanan Seenisamy
- Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra IV Phase, Bommasandra, Jigani Link Road, Bangalore 560 099, India
| | - John Kallikat Augustine
- Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra IV Phase, Bommasandra, Jigani Link Road, Bangalore 560 099, India
| | - Marc Missotten
- Merck Serono S.A., 9 Chemin des Mines, CH-1202 Geneva, Switzerland
| | - Yves Humbert
- Merck Serono S.A., 9 Chemin des Mines, CH-1202 Geneva, Switzerland
| | - Christophe Cleva
- Merck Serono S.A., 9 Chemin des Mines, CH-1202 Geneva, Switzerland
| | - Nada Abla
- Merck Serono S.A., 9 Chemin des Mines, CH-1202 Geneva, Switzerland
| | - Hamina Daff
- Merck Serono S.A., 9 Chemin des Mines, CH-1202 Geneva, Switzerland
| | - Olivier Schott
- Merck Serono S.A., 9 Chemin des Mines, CH-1202 Geneva, Switzerland
| | | | | | - Delphine Rivron
- Merck Serono S.A., 9 Chemin des Mines, CH-1202 Geneva, Switzerland
| | - Ingrid Hamernig
- Merck Serono S.A., 9 Chemin des Mines, CH-1202 Geneva, Switzerland
| | | | - Marilène Gaudet
- Merck Serono S.A., 9 Chemin des Mines, CH-1202 Geneva, Switzerland
| | | | - Pierre Juillard
- Merck Serono S.A., 9 Chemin des Mines, CH-1202 Geneva, Switzerland
| | - Zoe Johnson
- Merck Serono S.A., 9 Chemin des Mines, CH-1202 Geneva, Switzerland
| |
Collapse
|
20
|
Luker T, Bonnert R, Schmidt J, Sargent C, Paine SW, Thom S, Pairaudeau G, Patel A, Mohammed R, Akam E, Dougall I, Davis AM, Abbott P, Brough S, Millichip I, McInally T. Switching between agonists and antagonists at CRTh2 in a series of highly potent and selective biaryl phenoxyacetic acids. Bioorg Med Chem Lett 2011; 21:3616-21. [PMID: 21592791 DOI: 10.1016/j.bmcl.2011.04.101] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2011] [Revised: 04/18/2011] [Accepted: 04/21/2011] [Indexed: 11/26/2022]
Abstract
A novel series of biaryl phenoxyacetic acids was discovered as potent, selective antagonists of the chemoattractant receptor-homologous expressed on Th2 lymphocytes receptor (CRTh2 or DP2). A hit compound 4 was discovered from high throughput screening. Modulation of multiple aryl substituents afforded both agonists and antagonists, with small changes often reversing the mode of action. Understanding the complex SAR allowed design of potent antagonists such as potential candidate 34.
Collapse
Affiliation(s)
- Tim Luker
- Medicinal Chemistry, AstraZeneca R&D Charnwood, Loughborough, Leicestershire, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Ulven T, Kostenis E. Novel CRTH2 antagonists: a review of patents from 2006 to 2009. Expert Opin Ther Pat 2010; 20:1505-30. [PMID: 20946089 DOI: 10.1517/13543776.2010.525506] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
IMPORTANCE OF THE FIELD The receptor CRTH2 (also known as DP₂) is an important mediator of the inflammatory effects of prostaglandin D₂ and has attracted much attention as a therapeutic target for the treatment of conditions such as asthma, COPD, allergic rhinitis and atopic dermatitis. AREAS COVERED IN THIS REVIEW The validation of CRTH2 as a therapeutic target and the early antagonists are summarized, CRTH2 antagonists published in the patent literature from 2006 to 2009 are comprehensively covered and a general update on the recent progress in the development of CRTH2 antagonists for the treatment of inflammatory diseases is provided. WHAT THE READER WILL GAIN Insight into the validation of CRTH2 as a therapeutic target, a comprehensive overview of the development of new CRTH2 ligands between 2006 and 2009, and a general overview of the state of the art. TAKE HOME MESSAGE Many diverse potent CRTH2 antagonists are now available, and several are in or on the way into the clinic. It is still early to draw final conclusions, but preliminary results give reason for optimism, and the prospect that we will see new CRTH2 antagonists reaching the market for the treatment of asthma, rhinitis, atopic dermatitis and/or COPD seems good.
Collapse
Affiliation(s)
- Trond Ulven
- University of Southern Denmark, Department of Physics and Chemistry, Denmark.
| | | |
Collapse
|
22
|
Stebbins KJ, Broadhead AR, Correa LD, Scott JM, Truong YP, Stearns BA, Hutchinson JH, Prasit P, Evans JF, Lorrain DS. Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation. Eur J Pharmacol 2010; 638:142-9. [DOI: 10.1016/j.ejphar.2010.04.031] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2009] [Revised: 03/23/2010] [Accepted: 04/19/2010] [Indexed: 01/24/2023]
|
23
|
Tumey LN, Robarge MJ, Gleason E, Song J, Murphy SM, Ekema G, Doucette C, Hanniford D, Palmer M, Pawlowski G, Danzig J, Loftus M, Hunady K, Sherf B, Mays RW, Stricker-Krongrad A, Brunden KR, Bennani YL, Harrington JJ. 3-Indolyl sultams as selective CRTh2 antagonists. Bioorg Med Chem Lett 2010; 20:3287-90. [DOI: 10.1016/j.bmcl.2010.04.046] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2010] [Revised: 04/08/2010] [Accepted: 04/12/2010] [Indexed: 10/19/2022]
|
24
|
Grimstrup M, Receveur JM, Rist Ø, Frimurer TM, Nielsen PA, Mathiesen JM, Högberg T. Exploration of SAR features by modifications of thiazoleacetic acids as CRTH2 antagonists. Bioorg Med Chem Lett 2010; 20:1638-41. [DOI: 10.1016/j.bmcl.2010.01.092] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2009] [Revised: 01/10/2010] [Accepted: 01/12/2010] [Indexed: 11/29/2022]
|
25
|
Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 1. Bioorg Med Chem Lett 2010; 20:1177-80. [DOI: 10.1016/j.bmcl.2009.12.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2009] [Accepted: 12/01/2009] [Indexed: 11/20/2022]
|
26
|
Grimstrup M, Rist Ø, Receveur JM, Frimurer TM, Ulven T, Mathiesen JM, Kostenis E, Högberg T. Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 2. Bioorg Med Chem Lett 2010; 20:1181-5. [DOI: 10.1016/j.bmcl.2009.12.015] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2009] [Revised: 12/02/2009] [Accepted: 12/02/2009] [Indexed: 01/28/2023]
|
27
|
Martins MAP, Frizzo CP, Moreira DN, Buriol L, Machado P. Solvent-Free Heterocyclic Synthesis. Chem Rev 2009; 109:4140-82. [DOI: 10.1021/cr9001098] [Citation(s) in RCA: 518] [Impact Index Per Article: 34.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Marcos A. P. Martins
- Núcleo de Química de Heterociclos (NUQUIMHE), Departamento de Química Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil
| | - Clarissa P. Frizzo
- Núcleo de Química de Heterociclos (NUQUIMHE), Departamento de Química Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil
| | - Dayse N. Moreira
- Núcleo de Química de Heterociclos (NUQUIMHE), Departamento de Química Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil
| | - Lilian Buriol
- Núcleo de Química de Heterociclos (NUQUIMHE), Departamento de Química Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil
| | - Pablo Machado
- Núcleo de Química de Heterociclos (NUQUIMHE), Departamento de Química Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil
| |
Collapse
|
28
|
|
29
|
Caramori G, Groneberg D, Ito K, Casolari P, Adcock IM, Papi A. New drugs targeting Th2 lymphocytes in asthma. J Occup Med Toxicol 2008; 3 Suppl 1:S6. [PMID: 18315837 PMCID: PMC2259400 DOI: 10.1186/1745-6673-3-s1-s6] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Asthma represents a profound worldwide public health problem. The most effective anti-asthmatic drugs currently available include inhaled beta2-agonists and glucocorticoids and control asthma in about 90-95% of patients. The current asthma therapies are not cures and symptoms return soon after treatment is stopped even after long term therapy. Although glucocorticoids are highly effective in controlling the inflammatory process in asthma, they appear to have little effect on the lower airway remodelling processes that appear to play a role in the pathophysiology of asthma at currently prescribed doses. The development of novel drugs may allow resolution of these changes. In addition, severe glucocorticoid-dependent and resistant asthma presents a great clinical burden and reducing the side-effects of glucocorticoids using novel steroid-sparing agents is needed. Furthermore, the mechanisms involved in the persistence of inflammation are poorly understood and the reasons why some patients have severe life threatening asthma and others have very mild disease are still unknown. Drug development for asthma has been directed at improving currently available drugs and findings new compounds that usually target the Th2-driven airway inflammatory response. Considering the apparently central role of T lymphocytes in the pathogenesis of asthma, drugs targeting disease-inducing Th2 cells are promising therapeutic strategies. However, although animal models of asthma suggest that this is feasible, the translation of these types of studies for the treatment of human asthma remains poor due to the limitations of the models currently used. The myriad of new compounds that are in development directed to modulate Th2 cells recruitment and/or activation will clarify in the near future the relative importance of these cells and their mediators in the complex interactions with the other pro-inflammatory/anti-inflammatory cells and mediators responsible of the different asthmatic phenotypes. Some of these new Th2-oriented strategies may in the future not only control symptoms and modify the natural course of asthma, but also potentially prevent or cure the disease.
Collapse
Affiliation(s)
- Gaetano Caramori
- Dipartimento di Medicina Clinica e Sperimentale, Centro di Ricerca su Asma e BPCO, Università di Ferrara, Ferrara, Italy
| | - David Groneberg
- Institute of Occupational Medicine, Charité- Universitätsmedizin Berlin, Free University and Humboldt University, Berlin, Germany
| | - Kazuhiro Ito
- Airway Disease Section, National Heart and Lung Institute, Imperial College of London, London, UK
| | - Paolo Casolari
- Dipartimento di Medicina Clinica e Sperimentale, Centro di Ricerca su Asma e BPCO, Università di Ferrara, Ferrara, Italy
| | - Ian M Adcock
- Airway Disease Section, National Heart and Lung Institute, Imperial College of London, London, UK
| | - Alberto Papi
- Dipartimento di Medicina Clinica e Sperimentale, Centro di Ricerca su Asma e BPCO, Università di Ferrara, Ferrara, Italy
| |
Collapse
|
30
|
Ulven T, Gallen MJ, Nielsen MC, Merten N, Schmidt C, Mohr K, Tränkle C, Kostenis E. Synthesis and in vitro evaluation of a selective antagonist and the corresponding radioligand for the prostaglandin D2 receptor CRTH2. Bioorg Med Chem Lett 2007; 17:5924-7. [PMID: 17845848 DOI: 10.1016/j.bmcl.2007.07.080] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2007] [Revised: 07/23/2007] [Accepted: 07/24/2007] [Indexed: 11/17/2022]
Abstract
Synthesis and preliminary in vitro biological evaluation of a selective high-affinity CRTH2 antagonist is described. The stability of an N-benzyl group facilitated synthesis of the corresponding radioligand by tritiation of a brominated precursor. The compound [(3)H]TRQ11238 represents the first selective CRTH2 antagonist radioligand and exhibited a specific radioactivity of 52 Ci/mmol and a pK(d) of 9.0.
Collapse
Affiliation(s)
- Trond Ulven
- Department of Physics and Chemistry, University of Southern Denmark, Campusvej 55, DK-5230 Odense M, Denmark
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Sandham DA, Aldcroft C, Baettig U, Barker L, Beer D, Bhalay G, Brown Z, Dubois G, Budd D, Bidlake L, Campbell E, Cox B, Everatt B, Harrison D, Leblanc CJ, Manini J, Profit R, Stringer R, Thompson KS, Turner KL, Tweed MF, Walker C, Watson SJ, Whitebread S, Willis J, Williams G, Wilson C. 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett 2007; 17:4347-50. [PMID: 17531480 DOI: 10.1016/j.bmcl.2007.05.019] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2007] [Revised: 05/04/2007] [Accepted: 05/08/2007] [Indexed: 11/20/2022]
Abstract
High throughput screening identified a phenoxyacetic acid scaffold as a novel CRTh2 receptor antagonist chemotype, which could be optimised to furnish a compound with functional potency for inhibition of human eosinophil shape change and oral bioavailability in the rat.
Collapse
Affiliation(s)
- David A Sandham
- Global Discovery Chemistry, Novartis Institutes of Biomedical Research, Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
|